Data processing: artificial intelligence – Neural network – Structure
Patent
1996-01-24
1998-08-04
Davis, George B.
Data processing: artificial intelligence
Neural network
Structure
706 16, 706 31, 706902, 706924, G06F 1518
Patent
active
057907617
ABSTRACT:
A process is set forth in which cancer of the colon is assessed in a patient. The probabilities of developing cancer involves the initial step of extracting a set of sample body fluids from the patient. Fluids can be evaluated to determine certain marker constituents in the body fluids. Fluids which are extracted have some relationship to me development of cancer, precancer or tendency toward cancerous conditions. The body fluid markers are measured and other quantified. The marker data then is evaluated using a nonlinear technique exemplified through the use of a multiple input and multiple output neural network having a variable learning rate and training rate. The neural network is provided with data from other patients for the same or similar markers. Data from other patients who did and did not have cancer is used in the leaning of the neural network which thereby processes the data and provides a determination that the patient has a cancerous condition, precancer cells or a tendency towards cancer.
REFERENCES:
patent: 4725538 (1988-02-01), Senger
patent: 4732862 (1988-03-01), Bartorelli
patent: 4996298 (1991-02-01), Salem et al.
patent: 5260871 (1993-11-01), Goldberg
patent: 5324822 (1994-06-01), Duffy
patent: 5416025 (1995-05-01), Krepinsky et al.
patent: 5455159 (1995-10-01), Mulshine et al.
patent: 5463548 (1995-10-01), Asada et al.
patent: 5486456 (1996-01-01), Xu et al.
patent: 5580740 (1996-12-01), Yoshida et al.
patent: 5622171 (1997-04-01), Asada et al.
patent: 5635605 (1997-06-01), Guerrero et al.
patent: 5639622 (1997-06-01), Bosslet et al.
Ornithine Decarboxylase as a Marker for Colorectal Polyps and Cancer, Luk, et al., Prog. Clin. Ciol. Res. 279:1988, 227-39.
Longitudinal Compliance with Annual Screening for Fecal Occult Blood, Minnesota Colon Cancer Control Study, Thomas. et al., Am. J. Epidermiol, 142:2, 1995, Jul. 15, 176-82.
Murine Monoclonal Antibodies to Colon-Specific Antigen P., Gold, et al., Cancer Res., 50:19, 1990 Oct. 1, 6405-9.
Screening of Average-Risk Individuals for Colorectal Cancer. Who Collaborating Centre for the Prevention of Colorectal Cancer, Winawer, et al., Bull. World Health Organ., 68:4, 1990 505-13.
The Estimation of Sensitivity and Specificity in Colorectal Cancer Screening Methods, Walter, et al., Cancer Detect. Prev., 15:6, 1991, 465-9.
Specificity and Immunobiological Properties of Monoclonal Antibody IMH2, Established After Immunization with LE(B)/LE(A) Glycosphingolipid, a Nvoel Extended Type 1 Chain Antigen, Ito, et al., Cancer Res., 52:13, 1992 Jul. 1, 3739-45.
Short Chain Fatty Acid Distributions of Enema Samples from a Sigmoidoscopy Population; and Association of High Acetate and Low Butyrate Ratios with Adenomatous Polyps and Colon Cancer; Weaver, et al., Gut, 29:11, 1988 Nov., 1539-43.
Biochemical Markers for Colorectal Cancer, Diagnostic and Therapeutic Implications, Hackford, W.S., Surg. Clin. North Am., 73:1, 1993 Feb., 85-102.
Screening for Colorectal Cancer with Fecal Occult Blood Testing and 85:16, 1993 Aug. 18, 1311-8.
Mucosal Origin and Shedding of an Early Colonic Tumor Marker Defined by ADNAB-9 Monoclonal Antibody, Tibi, et al., Scand. J. Gastroenterol, 28:12,1993 Dec., 1025-34.
Accuracy of Immunological Fecal Occult Blood Testing for Colorectal Cancer Screening, Nakama, et al., Prev. Med., 23:3, 1994 May, 309-13. Tool of Lower Gastrointestinal Tract Diseases!, Meguro, T., Hokkaido Igaku Zasshi, 69:4, 1994 Jul., 995-1009.
ROC Curves and the Areas Under Them for Dichotomized Tests: Empirical Findings for Logistically and Normally Distributed Diagnostic Test Results, Van Der Schouw, et al., Med. Decis. Making, 14:4, 1994 Oct.-Dec., 374-81.
A National Population-Based Study of Incidence of Colorectal Cancer and Age. Implications for Screening in Older Americans, Cooper, et al., Cancer, 75:2, 1995, Feb. 1, 775-81.
Selections from Current Literature: Screening for Colorectal Cancer, Rahman, et al., Fam. Pract., 11:3, 1994 Sep. 333-9.
Significance of Tumour Markers in Colorectal Carcinoma Associated with Schistosomiasis, Noeman, et al., Bangladesh Med. Res. Counc. Bull., 20:1, 1994 Apr., 12-20.
Screening for Colorectal Cancer: Reasons for Refusal of Faecal Occult Blood Testing in a General Practice in England, Hynam, et al., J. Epidemiol Community Health, 49:1, 1995 Feb., 84-6.
A Case-Control Study to Evaluate Efficacy of Screening For Faecal Occult Blood, Lazovich, et al., J. Med. Screen., 2:2, 1995, 84-9.
Screening or Cancer in High Risk Families, Narol, S.A., Clin. Biochem., 28:4, 1995 Aug., 367-72.
The Impact of Mailing Fecal Occult Blood Test Kits on Return Rate in a Community Cancer Screening Center, Mahlon, S.M., Oncol. Nurs. Forum, 22:8, 1995 Sep., 1259-63.
Predictive Value of Signs and Symptoms for Colorectal Cancer in Patients with Rectal Bleeding in General Pracice, Fijten, et al., Fam. Pract., 12:3, 1995 Sep., 279-86.
Evaluation and Comparison of an Immunochemical and a Guaiac Faecal Occult Blood Screening Test for Colorectal Neoplasia, Rozen, et al., Eur. J. Cancer Prev., 4:6, 1995 Dec., 475-81.
Escherichia Coli Heat-Stable Enterotoxin Receptors. A Novel Marker For Colorectal Tumors, Carrithers, et al., Dis. Colon Rectum, 39:2, 1996 Feb., 171-81.
Carcinoembryonic Antigen (CEA) Enzyme Immunoassay Test Kit, Reynoso, G., et al., Journal of the American Medical Association, 220:361-365, 1972.
Pancreatic Oncofetal Antigen and Carbohydrate Antigen 19-9 in Sera of Patients with Cancer of the Pancreas, Clinical Chemistry, 35, 405 (1989).
A Double Monoclonal Immunoenzymometric Assay for Alpha-Fetoprotein Modified for Increased Analytical Precision, Shahangian, et al., The American Association of Clinical Chemistry 1987.
Improved Method to Determine Lipid Bound Sialic Acid in Plasma or Serum, Katopodis, et al., Research Communications in Chemical Pathology and Pharmacology, Oct. 1980, vol. 30.
Salvans et al, "An Empirical Comparison of Backpropagation and Multivariable Discriminant Analysis To the prediction of Colon Cancer Recurrence After Surgical Treatment", INNC 1990.
Wu et al, "Application of Neural Networks to Mammographic Diagnosis of Breast Cancer", 76th Science Assembly and Annual Metting of the Rad. Society of North America, Nov. 1990.
Ciamac Moallemi, "Classifying Cells for Cancer Diagnosis Using Neural Networks" IEEE Expert, Dec. 1991.
Salvans et al, "An Epidemiologic Approach to Computerized Medical Diagnosis-AEDMI Program", Computer. Biol. Med., 1990, vol. 20, No. 6.
J. N. DeRoach, "Neural Networks-An Artificial Intelligence Approch to the Analysis of clinical data", Australasian Physical & Engineering Science in Medicine, vol. 12, No. 2, 1989.
Austin et al, Application of Neural Networks to the Interpetation of Laboratory Data in Cancer Diagnosis, Clin. Chem., 1992.
Paganuzzi et al, "Clinical Evaluation of New Tumor -Associated Antigens", Human Tumor Makers, 1987.
Tantu et al, "Evaluation of Serum Sialic Acid and Carcinoembryonic Antigen for the Detection of Early-stage Colorectal Cancer", Journal of Clinical Laboratory Analysis, 1991.
Jacobs et al, "Clinical Use of Tumor Markers in Oncology", Current Problems in Cancer, 1991.
Guadagni et al, "Clinical Evaluation of Serum Tumor-Associated Glycoprotein -72 as a Novel Tumer Marker for Colorectal Cancer Patients", Journal of Surgical Oncology Supplement, 1991.
R. Lamerz, "CEA determination in the follow-up of extracolorectal neoplasms", Int. Jour. of Biol. Markers (Italy) 1992.
Heseltine Gary L.
Warrington Richard E.
LandOfFree
Method and apparatus for the diagnosis of colorectal cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and apparatus for the diagnosis of colorectal cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and apparatus for the diagnosis of colorectal cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1187678